Drs Kathy Miller and Lajos Pusztai discuss predicting which patients will have a PCR, and the impact this has on new treatments or reducing the intensity of treatments.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002987. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Overall Survival With Pembrolizumab in Early-Stage Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39282906/

I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33312344/

Treatment Efficacy Score-Continuous Residual Cancer Burden-Based Metric to Compare Neoadjuvant Chemotherapy Efficacy Between Randomized Trial Arms in Breast Cancer Trials https://pubmed.ncbi.nlm.nih.gov/35513244/

Predictors of Pathological Complete Response to Neoadjuvant Treatment and Changes to Post-Neoadjuvant HER2 Status in HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33526875/

Clinical Decision Impact of HER2DX, an Algorithm-Powered Genomic Diagnostic in Early-Stage HER2-Positive Breast Cancer: Results From a Prospective Real-World Study https://www.sciencedirect.com/science/article/pii/S2949820125000128

Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Therapy Response and Prognosis in Breast Cancer: A Multicenter Retrospective Study Based on Chinese Population https://pubmed.ncbi.nlm.nih.gov/41094431/

Predicting Pathologic Complete Response (pCR) From Clinicopathologic Variables and HER2DX Genomic Test in Stage II/III HER2+ Breast Cancer Treated With Taxane, Trastuzumab, and Pertuzumab (THP): Secondary Results From the EA1181/CompassHER2 pCR Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.501

MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data https://pubmed.ncbi.nlm.nih.gov/40796181/

Oncotype DX Breast Recurrence Score®: A Review of Its Use in Early-Stage Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32613290/

Toll-like Receptor-Based Strategies for Cancer Immunotherapy https://pubmed.ncbi.nlm.nih.gov/34124272/

The Tale of TILs in Breast Cancer: A Report From The International Immuno-Oncology Biomarker Working Group https://pubmed.ncbi.nlm.nih.gov/34853355/